Tonix Pharmaceuticals (US:TNXP)2023-03-29 15:42Financial Status - As of December 31, 2022, Tonix Pharmaceuticals had approximately $120 million in cash and cash equivalents and no debt[38] Pipeline Highlights - CNS Portfolio - TNX-102 SL for fibromyalgia is in Mid-Phase 3 with >50% enrollment in the confirmatory Phase 3 study (RESILIENT)[8, 11] - TNX-102 SL for fibromyalgia-type Long COVID is in Phase 2 with trial enrollment in process[10, 21] - TNX-601 ER for depression is in Phase 2 with the UPLIFT study currently enrolling[26] - TNX-1900 for prevention of chronic migraine is in Phase 2 with enrolling[59] Pipeline Highlights - Other Areas - TNX-1300 for cocaine intoxication has FDA Breakthrough Therapy Designation and is in Mid-Phase 2, with a targeted 2Q 2023 start for a new Phase 2 trial[7] - TNX-1500 for organ transplant rejection/autoimmune conditions is Phase 1 ready, targeted for 2Q 2023 start[59] - TNX-801 for smallpox and mpox vaccine is in Phase 1, targeted for 2H 2023 start[59] Key Upcoming Milestones - Interim analysis results for the Phase 3 RESILIENT study of TNX-102 SL for fibromyalgia are expected in 2Q 2023[176] - Interim analysis results for the Phase 2 PREVENTION study of TNX-1900 for chronic migraine are expected in 4Q 2023[176] - Interim analysis results for the Phase 2 UPLIFT study of TNX-601 ER for major depressive disorder are expected in 4Q 2023[176] - Topline results of the Phase 3 RESILIENT study of TNX-102 SL for fibromyalgia are expected in 4Q 2023[176]